NCT07199816

Brief Summary

Comparing the analgesic effect of caudal epidural versus combined lumbar sympathetic block with caudal epidural in patients undergoing redo spinal surgery.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
3mo left

Started Jun 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
Jun 2025Aug 2026

Study Start

First participant enrolled

June 1, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

September 14, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

September 30, 2025

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 20, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Last Updated

September 30, 2025

Status Verified

March 1, 2025

Enrollment Period

1.1 years

First QC Date

September 14, 2025

Last Update Submit

September 22, 2025

Conditions

Keywords

pain control

Outcome Measures

Primary Outcomes (1)

  • Pain intensity (Numerical Rating Scale - NRS)

    Pain intensity will be assessed using the Numerical Rating Scale (NRS), where patients rate their pain from 0 (no pain) to 10 (worst possible pain). NRS scores will be compared between the two groups (caudal epidural block vs. combined lumbar sympathetic and caudal epidural block) to evaluate the long-term effectiveness of the interventions.

    over 3 months postoperative

Secondary Outcomes (7)

  • Postoperative pain intensity (NRS)

    over 24 hours after surgery

  • Time to first postoperative analgesic request

    postoperative period up to hospital discharge

  • Total postoperative morphine consumption

    postoperative period up to hospital discharge

  • Long-term pain relief using WHO pain relief criteria

    over 3 months after the procedure

  • Functional recovery and ambulation (EuroQol)

    over 3 months postoperative

  • +2 more secondary outcomes

Study Arms (2)

Group C

ACTIVE COMPARATOR

Group C (n=32): this group will receive fluoroscopy guided caudal epidural block. Under fluoroscopic guidance and the patients in prone position, caudal epidural injection will be achieved. A pillow will be inserted under the pelvic bones for better exposure and accessibility of thesacral hiatus. Betadine will be used for sterilization of the sacrococcygeal area and palpation of the coccygeal tip. Upon localization of the sacral hiatus, a 22-gauge, 3.5-inch length spinal needle (Spinocan®, BRAUN, Melsungen, Germany) with the image intensifier will be used to inject 1 mL of contrast media (Omnipaque 300; GE Healthcare, Carrigtohill, Co. Cork, Ireland). After confirming the right needle position and excluding intravascular, intrathecal, and soft tissue infiltration, 10 cc of the treatment drug (8 ml of 0.5%lidocaine mixed with 2ml of 8 mg dexamethasone) will be injected.

Procedure: Fluoroscopy-Guided Caudal Epidural Block

Group LC

ACTIVE COMPARATOR

Group LC: Group (n=32): this group will receive combined fluoroscopy guided caudal epidural block and lumbar sympathetic ganglion block. Under fluoroscopic guidance, LSGB will be performed. The block level and side will be determined. Patients will be kept in the prone position while C-arm (GE OEC 9900 C- of the anteroposterior, oblique, and lateral view are examined to verify the correct entrance sit. The skin will be prepared in an aseptic manner. Approach the anterolateral border of the inferior sec of the L2 vertebral body or the upper portion of the L3 vertebral body of the affected side where the pain exists, using a 21-gauge Chiba needle. Following the confirmation of the needle location via fluoroscopic imaging, an aspiration test will be performed in order to rule out the presence of blood, following by injection of a contrast medium. Following that, 2 mL of 8mg dexamethasone will be diluted with 8 mL of 1% lidocaine and injected unilaterally at one level.

Procedure: Combined Lumbar Sympathetic Ganglion Block and Caudal Epidural Block

Interventions

Under fluoroscopic guidance, the patient in the prone position will receive a caudal epidural injection through the sacral hiatus. A 22-gauge, 3.5-inch spinal needle (Spinocan®, BRAUN) is used to inject 1 mL of contrast media (Omnipaque 300) to confirm correct needle placement. Then, 10 mL of treatment solution (8 mL of 0.5% lidocaine and 2 mL of 8 mg dexamethasone) is administered.

Group C

Patients will receive both a caudal epidural block and a lumbar sympathetic ganglion block (LSGB) under fluoroscopic guidance. The LSGB is performed at the L2 or L3 vertebral body on the affected side using a 21-gauge Chiba needle. After confirming needle position with contrast imaging, 10 mL of solution (2 mL of 8 mg dexamethasone + 8 mL of 1% lidocaine) is injected. A caudal block is then performed as described above.

Group LC

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 40-70 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status I to III.
  • Undergoing lumbar spine surgery level L4-5/ L5-S1 for the second time.
  • Duration of chronic low back pain \> 3months.

You may not qualify if:

  • Emergency surgeries.
  • Bleeding disorder.
  • patient refusal for the procedure.
  • Pregnancy.
  • Neoplastic diseases, allergies to contrast.
  • Liver failure or kidney failure .

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kasr Al-Ainy Medical School, Cairo University

Cairo, Egypt

Location

Related Links

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Hebatullah Mohammed Abdelmageed, Principle Investigator

Study Record Dates

First Submitted

September 14, 2025

First Posted

September 30, 2025

Study Start

June 1, 2025

Primary Completion (Estimated)

June 20, 2026

Study Completion (Estimated)

August 1, 2026

Last Updated

September 30, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Participant privacy and confidentiality concerns; data sharing is not permitted under institutional policy.

Locations